Feedback

Browsing by N


Use an asterisk (*) for partial word searches (e.g. pemph*)

57 results found.

1.
2.
3.
Ordering Recommendation:   Confirm diagnosis of anti-NMDAR encephalitis.
4.
Ordering Recommendation:   Confirm diagnosis of NMDAR antibody encephalitis.
5.
Ordering Recommendation:   Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis. May assist when diagnosing and monitoring mast-cell activation disorders or when evaluating histamine production over a longer time frame.
6.
7.
8.
9.
10.
11.
Ordering Recommendation:   May help rule out narcolepsy when clinical history and sleep studies are inconclusive.
12.
Ordering Recommendation:   Aids in management of individuals receiving natalizumab therapy.
13.
14.
15.
16.
Ordering Recommendation:   Preferred test for detecting Neisseria gonorrhoeae in variety of specimens. This test does not include confirmation of positive results by an alternative nucleic acid target. If confirmation of positive results by an alternative nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).
17.
Ordering Recommendation:   Use to assess immunocompetence following Neisseria meningitidis vaccination. To assess suspected immunodeficiency, use pre- and postvaccination serology. Do not use for diagnosis of infection or serotyping.
18.
19.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
20.
Ordering Recommendation:   Acceptable test to confirm a suspected diagnosis of neurofibromatosis type 1 (NF1) in individuals not meeting NIH clinical criteria.
21.
Ordering Recommendation:   Preferred test to confirm a suspected diagnosis of neurofibromatosis type 1 (NF1) in individuals not meeting NIH clinical criteria.
22.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
23.
24.
25.
26.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
27.
28.
29.
Ordering Recommendation:   Aids in discriminating between a paraneoplastic neurologic syndromes and other encephalitis of unknown origin.
30.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
31.
Ordering Recommendation:   Functional assay helpful in screening for CGD.
32.
33.
34.
35.
36.
Ordering Recommendation:   Preferred test for documenting nicotine cessation over time. Use to detect and monitor nicotine, cotinine, and trans-3'-hydroxycotinine in serum or plasma.
37.
Ordering Recommendation:   Assess active exposure to nicotine and compliance with smoking-cessation programs. Use to confirm cotinine screening results.
38.
Ordering Recommendation:   Diagnostic testing for Niemann-Pick disease, type A. Carrier screening for Niemann-Pick disease, type A.
39.
Ordering Recommendation:   Diagnostic testing for Niemann-Pick disease, type A.
40.
41.
Ordering Recommendation:   Use as an aid in the diagnosis of urothelial carcinoma in conjunction with standard diagnostic procedures and monitoring tumor recurrence.
42.
43.
Ordering Recommendation:   Acceptable second-line test when antiphospholipid syndrome (APS) is strongly suspected and aPL criteria tests are negative.
44.
Ordering Recommendation:   Screens for trisomy 13, 18, 21; Turner syndrome; and triploidy. Recommended for women at high risk for a fetal chromosomal aneuploidy. This includes women who 1) are 35 years or older at delivery, 2) have had a previous child with aneuploidy, 3) have a fetus with identified ultrasound anomalies associated with the above aneuploidies, or 4) have screened positive by maternal serum screening testing in the current pregnancy.
45.
Ordering Recommendation:   Screens for trisomy 13, 18, 21; Turner syndrome; triploidy; AND microdeletions responsible for 22q11.2 deletion,1p36 deletion, Angelman, Prader-Willi, and cri-du-chat syndromes. PRETEST GENETIC COUNSELING RECOMMENDED TO EXPLAIN MICRODELETION SCREENING BENEFITS AND LIMITATIONS. Recommended for women at high risk for a fetal aneuploidy who wish to also screen for the listed microdeletions - includes women who 1) are 35 years or older at delivery, 2) have had a previous child with aneuploidy, 3) have a fetus with identified ultrasound anomalies associated with the above aneuploidies, or 4) have screened positive by maternal serum screening testing in the current pregnancy.
46.
Ordering Recommendation:   Determine fetal genotype when mother has clinically significant alloantibody AND father is heterozygous for RHD or not available for testing.
47.
Ordering Recommendation:   Only intended for use in patients with non-alcoholic liver disease (NAFLD); results may be inaccurate in patients with other etiologies of liver disease.
48.
Ordering Recommendation:   Preferred test for individuals with clinical phenotype of Noonan syndrome, cardiofaciocutaneous syndrome, Costello syndrome, LEOPARD syndrome, Legius syndrome, or Noonan-like syndrome.
49.
Ordering Recommendation:   Prenatal testing for fetus with ultrasound findings suggestive of Noonan syndrome, such as cystic hygroma, increased nuchal translucency, or polyhydramnios.
50.
Ordering Recommendation:   Acceptable initial test to confirm a clinical diagnosis of Noonan syndrome or LEOPARD syndrome.
51.
Ordering Recommendation:   Acceptable initial test to confirm a clinical diagnosis of Noonan syndrome or LEOPARD syndrome.
52.
Ordering Recommendation:   Acceptable secondary test if no pathogenic mutations are detected with PTPN11 testing.
53.
54.
Ordering Recommendation:   Test only measures nortriptyline concentration. If amitriptyline will be administered, order Amitriptyline and Nortriptyline (0090158).
55.
Ordering Recommendation:   Initial test for prognostication of CN-AML.
56.
Ordering Recommendation:   Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, melanoma and colorectal cancer).
57.
Ordering Recommendation:   Use Nuclear Antibody (ANA) by IFA, IgG as a follow up to a positive ANA screening test.